Prof. Dr. Bernd Wullich


Lehrstuhl für Urologie

Publications (Download BibTeX)

Go to first page Go to previous page 1 of 11 Go to next page Go to last page

Schmidkonz, C., Cordes, M., Goetz, T.I., Prante, O., Kuwert, T., Ritt, P.,... Bäuerle, T. (2019). 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Annals of Nuclear Medicine.
Eckstein, M., Sailer, V., Nielsen, B.S., Wittenberg, T., Wiesmann, V., Lieb, V.,... Wach, S. (2019). Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays. Laboratory Investigation.
Wach, S., Brandl, M., Borchardt, H., Weigelt, K., Lukat, S., Nolte, E.,... Aigner, A. (2019). Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo. Molecular Therapy - Nucleic Acids, 16, 272-283.
Kahlmeyer, A., Stoehr, C.G., Hartmann, A., Goebell, P., Wullich, B., Wach, S.,... Erlmeier, F. (2019). Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. Journal of Clinical Medicine, 8(5).
Wullich, B., & Wiedemann, A. (2019). Geriatric urology (Geriatrische Urologie). Urologe, 58(4), 369-.
Polifka, I., Agaimy, A., Herrmann, E., Spath, V., Trojan, L., Stoeckle, M.,... Hartmann, A. (2019). High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. Human Pathology, 83, 212-223.
Merten, R., Ott, O., Haderlein, M., Bertz, S., Hartmann, A., Wullich, B.,... Fietkau, R. (2019). Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist.
Hirsch, K., Schwaiger, B., Kraske, S., & Wullich, B. (2019). Megaprepuce: presentation of a modified surgical technique with excellent cosmetic and functional results. Journal of Pediatric Urology.
Stoehr, R., Wendler, O.D., Giedl, J., Gaisa, N.T., Richter, G., Campean, V.,... Hartmann, A. (2019). No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis. Pathobiology, 86(2-3), 145-151.
Eckstein, M., Erben, P., Kriegmair, M.C., Worst, T.S., Weiss, C.-A., Wirtz, R.M.,... Erlmeier, F. (2019). Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European journal of cancer, 106, 234-243.

Last updated on 2016-05-05 at 05:06